Literature DB >> 16543046

Evaluation of multiple immune parameters after vaccination with modified live or killed bovine viral diarrhea virus vaccines.

A J Reber1, M Tanner, T Okinaga, A R Woolums, S Williams, D T Ensley, D J Hurley.   

Abstract

The development of immunity to vaccine antigen was examined using three prime/boost strategies and the progression of immune activities was evaluated over the course of 8 weeks. Calves were vaccinated and multiple immune parameters were evaluated using several methods to assess humoral or cellular immunity from the same samples in parallel. The three vaccination protocols used were a killed vaccine followed by a killed boost (killed/killed), MLV vaccine and boost (MLV/MLV), or a MLV vaccine and killed boost (MLV/killed). All the vaccines used included modified live IBR/PI3 viruses to make the bystander context as similar as possible. The Singer strain of BVDV was used as the source antigen in the killed vaccine, and the NADL strain of BVDV was used in the MLV vaccine. Controls received a vaccine containing only MLV IBR/PI3. The assessment panel measured SN titers, as well as lymphocyte proliferation, cytokine mRNA expression, intracellular cytokine production, and released IFN-gamma after in vitro stimulation with three strains of BVDV virus. MLV/MLV and MLV/killed groups developed significant SN titers to the type 1 BVDV virus strains, Singer and NADL, and low crossover titers were also seen to the type 2 strain, 890 over the evaluation period. These two groups showed significant proliferation in response to the NADL virus as compared to controls. Multiple immune assessments were conducted simultaneously to attempt to provide a broader, more in depth evaluation of immune response to these BVDV vaccination protocols. We observed that the correlation among most of the assays conducted were weak; the correlation between SN titers and cellular proliferation assays demonstrated a moderate correlation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16543046     DOI: 10.1016/j.cimid.2006.01.001

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  5 in total

1.  Characterization and comparison of cell-mediated immune responses following ex vivo stimulation with viral and bacterial respiratory pathogens in stressed and unstressed beef calves1.

Authors:  Veronica M Buhler; Kaycee R Cash; David J Hurley; Brent C Credille
Journal:  J Anim Sci       Date:  2019-07-02       Impact factor: 3.159

2.  Efficacy and durability of bovine virus diarrhea (BVD) virus killed vaccine adjuvanted with monolaurin.

Authors:  Maha Raafat Abd El Fadeel; Eman M Soliman; Ahmad Mohammad Allam; Mohamed F ElKersh; Rehab Mahmoud Abd El-Baky; Ahmad Mustafa
Journal:  PLoS One       Date:  2022-07-14       Impact factor: 3.752

3.  Priming Cross-Protective Bovine Viral Diarrhea Virus-Specific Immunity Using Live-Vectored Mosaic Antigens.

Authors:  Shehnaz Lokhandwala; Xin Fang; Suryakant D Waghela; Jocelyn Bray; Leo M Njongmeta; Andy Herring; Karim W Abdelsalam; Christopher Chase; Waithaka Mwangi
Journal:  PLoS One       Date:  2017-01-18       Impact factor: 3.240

4.  Immune response and onset of protection from Bovine viral diarrhea virus 2 infection induced by modified-live virus vaccination concurrent with injectable trace minerals administration in newly received beef calves.

Authors:  João H J Bittar; Roberto A Palomares; David J Hurley; Alejandro Hoyos-Jaramillo; Adriana Rodriguez; Agne Stoskute; Brianna Hamrick; Natalie Norton; Morgan Adkins; Jeremiah T Saliki; Susan Sanchez; Kensey Lauber
Journal:  Vet Immunol Immunopathol       Date:  2020-04-27       Impact factor: 2.046

5.  Mosaic Bovine Viral Diarrhea Virus Antigens Elicit Cross-Protective Immunity in Calves.

Authors:  Neha Sangewar; Wisam Hassan; Shehnaz Lokhandwala; Jocelyn Bray; Rachel Reith; Mary Markland; Huldah Sang; Jianxiu Yao; Bailey Fritz; Suryakant D Waghela; Karim W Abdelsalam; Christopher C L Chase; Waithaka Mwangi
Journal:  Front Immunol       Date:  2020-11-12       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.